EU Thumbs Up Signals First-Ever Approval For Leo’s Tralokinumab
UK Regulator Also Expected To Reach Decision On Approval Soon
Executive Summary
Leo’s moderate-to-severe atopic dermatitis drug is set to be approved for the first time worldwide.
You may also be interested in...
Galderma Reveals Long-Term Nemolizumab Data As It Prepares To Take On Dupixent
Galderma presented long-term extension data from its Phase III trials in atopic dermatitis and prurigo nodularis at AAD for its first-ever therapeutic biologic, taking on a formidable competitor.
Leo Pharma Strengthens Dermatology Position With Second Eczema Win
The company reported positive topline results from a second trial of its topical pan-JAK inhibitor, delgocitinib, in chronic hand eczema.
Leo CEO Bourdon Plots Return To Profit This Year
The Danish group has cut 300 jobs to shift to an external innovation sourcing model that will make Leo more competitive in the dermatology space and help it break even this year, CEO Christophe Bourdon tells Scrip.